At the ECCO 2025 Congress, researchers presented a study showing that machine learning can identify gut microbial biomarkers that differentiate IBD patients—particularly those with Crohn’s disease—from healthy individuals. The study analyzed stool samples from over 3,700 participants, finding that supervised machine learning had the highest diagnostic accuracy (AUC 0.971).
Trending
- 5 doctors weigh in on the promise, limitations of Grail’s multicancer test (Medtech Dive)
- IBS Pain Closely Linked to Interrelated Daily-Life Triggers (Physicians Weekly)
- First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication (Takeda)
- Industry Voices—How physician practices can grow and succeed without the support of private equity (Fierce Healthcare)
- Blood-Based CRC Test Upgrades Improve on Precancerous Lesion Detection (Medscape)
- Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing (Lucid Diagnostics)
- How Can GI Fellowship Programs Enhance Ambulatory Training? (Yale School of Medicine)
- VIOVOC Issued U.S. Patent for Ambient Sensing Technology That Decodes Gut Microbiome Signals (Business Wire)
